Expanding AI capabilities in their cardiac monitoring platform, PaceMate has appointed a new AI head.
PaceMate, a leading remote cardiac monitoring platform, has announced the appointment of Sean Shoffstall as its new Head of AI, Innovation, and Data Strategy. Shoffstall brings a wealth of experience from his previous roles at Beginly Health, Welby Health, Auditdata, and most recently, Cardiosense.
With over 1,000 hospitals, including major healthcare systems and cardiology centers worldwide, trusting PaceMate for improving remote cardiac monitoring news, Shoffstall's expertise is set to play a crucial role in further streamlining these processes.
PaceMate has centralised discrete data from a wide range of cardiac monitoring devices, EHR systems, and clinics' internal operations. Shoffstall's initial focus will be on surfacing the insights that matter most, optimising clinics' operational efficiency, and fuelling medical and industry research.
Shoffstall is committed to innovating responsibly with ethical AI practices and transparency at the core. He played a role in the launch of the first HIPAA-compliant AI-generated audiogram analysis tool in the industry, demonstrating his awareness of data sensitivities in the healthcare industry.
In his new role, Shoffstall will drive PaceMate's AI ambitions, transforming data-driven insights into automatic actions. His goal is to ensure that new AI applications handle data analysis and pattern recognition, enabling healthcare providers to spend more time on patient care.
Meanwhile, JR Finkelmeier, the recently appointed CEO of PaceMate, is driving innovation across the company's products and client services. PaceMate is dedicated to providing clinicians with software and services to improve patient care and overcome remote cardiac monitoring and operational roadblocks.
In other news, Cardiosense has received FDA clearance for its CardioTag Device, adding to the company's already substantial cardiac dataset, which is one of the most robust on the planet. Elsewhere, Biotricity and B-Secur have launched a device-neutral ambulatory cardiac monitoring platform.
As PaceMate continues to innovate and grow, Shoffstall's appointment marks an exciting new chapter. He plans to maintain a partnership approach with the over 1,000 clinics that already trust PaceMate, aiming to improve triage, enable population health, and fuel preventive strategies through the layering of AI and machine learning capabilities onto its data.
Read also:
- Is it advisable to utilize your personal health insurance in a publicly-funded medical facility?
- Dietary strategies for IBS elimination: Aims and execution methods
- Benefits, suitable dosage, and safety considerations for utilizing pumpkin seed oil in treating an overactive bladder
- Harmful Medical Remedies: A Misguided Approach to Healing
